Objectives: The aim of this study is to review the available literature on the efficacy and safety of agents used for prevention of RAS.
Introduction
The radial artery is fast becoming the preferred access site for performing coronary angiography and percutaneous coronary intervention (PCI) [1] . In UK, adoption of the transradial access site (TRA) for PCI has increased from 10% in 2006 to over 60% in 2012 [2] . TRA is associated with reduced mortality and major adverse cardiac events (MACE) in selected cohorts at high risk of bleeding complications [2] [3] [4] , thought to be related to a reduction in major access site related bleeding complications [1, 5] . Transradial access is also associated with improved patient comfort and has also shown to be the preferred access site amongst patients undergoing PCI and be more cost effective than transfemoral access [6] [7] [8] .
However, TRA approach is not without limitations, it is associated with a longer learning curve and complex procedures requiring large bore guide catheters are not always possible particularly in patients with small diameter radial arteries. Furthermore operators may encounter radial artery spasm (RAS) [9] during TRA particularly at the beginning of the learning curve, or when encountering radial anomalies. A previous review of 19 papers with 7,197 participants found that the incidence of RAS was 14.7% in patients in whom the radial artery was chosen as the access site for coronary angiography or PCI [10] .
RAS leads to patient discomfort, increased risk of vascular complications and procedure failure rate. Various drugs such as nitroglycerin, verapamil, isosorbide mononitrate are used to reduced the risk of RAS. However, there is high variability in practice amongst operators for administration of these drugs. Furthermore, there are no guidelines or recommendations for using such drugs in day-to-day practice. Therefore, we conducted a systematic review of the available literature to evaluate the efficacy of agents used for prevention of RAS.
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Methods
We searched MEDLINE and EMBASE on October 2014 using the broad search terms: "vasodilator" AND "radial artery occlusion" OR "radial artery spasm" OR "transradial." The search results were reviewed by two independent judicators (CSK, MR) for studies that met the inclusion criteria and relevant reviews. The bibliographies of included studies and relevant reviewers were screened for additional studies.
We included studies that evaluated any intra-arterial drug administered in the setting of TRA. The inclusion criteria was 1. Studies had to compare more than one agent or include a control group. There was no restriction based on sample size.
2. The studies had to evaluate some form of measure related to RAS such as incidence of RAS, change in diameter of radial artery and any adverse events associate with intra-arterial drug administration.
We excluded studies that administered drugs that were not intra-arterial and in-vitro studies.
Data was extracted from each study into preformatted spreadsheets. The data collected was on the year, country, number of participants, age of participants, % of male participants, participant inclusion criteria, and type of treatments, efficacy outcomes and safety outcomes. These results were narratively synthesized and trials with similar treatment arms were pooled using methods previous described [11] .
We also compared studies for secondary outcomes of procedure time, and procedure failure rate in setting of RAS prevention and radial artery occlusion.
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Results
Our search yielded 123 relevant articles and after screening and reviewing full manuscripts, 21 articles met the inclusion criteria with 22 clinical studies . The process of study selection is shown in Figure 1 .
The study design and participant characteristics of the included trials is shown in Table 1 . Majority of studies (n=14) used blinding and these studies took place between 1997-2007 in different centers around the world. There were a total of 8,777 participants (range of participants in each study 30 to 1,950) with an average age of 61 years and 70% were male participants. All studies took place in the setting of transradial access (TRA). Radial artery spasm was the most frequently evaluated outcome, which was evaluated for the efficacy of individual drugs in 14 studies (Table 3 ). For placebo, RAS rate was 12% (4 studies, 638 participants), which was similar to 2.5 mg of verapamil 12% (3 studies, 768 participants) but greater than 5 mg of verapamil (4%, 2 studies, 497 participants). For nicorandil, there was a much higher RAS rate compared to placebo (16%, 3 studies, 447 participants). The lowest rates of RAS was found for nitroglycerin at both 100 µg (4%) and 200 µg (2%) doses, isosorbide mononitrate (4%) and nicardipine (3%).
Combinations of different drugs were also evaluated in several studies [15, 16, [18] [19] [20] combining agents offered no advantage. The best studied combination of verapamil and A C C E P T E D M A N U S C R I P T
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nitroglycerin was evaluated in 5 studies [16, 17, [22] [23] [24] . The pooled results of these studies yielded 21% RAS rate (5 studies, 135/630) however, two studies [17, 23] reported unusually high rates of RAS (71% and 52% respectively) and differed from the other studies because the verapamil dose was low (100 µg). Excluding these studies the pooled rate of RAS for the verapamil/nitroglycerin combination was 9% (3 studies, 45/483).
Other outcomes
Several studies evaluate outcomes other than RAS. Abe et al found that ISDN was most potent vasodilator compared to verapamil, lignocaine and placebo [12] . While this study examined multiple doses, it was underpowered across each group. Boyer et al found that a combination of nitroglycerin and verapamil was associated with greater vasodilation compared to placebo [13] . Byrne et al found that magnesium is a more potent vasodilator than verapamil [14] . Carrillo et al found similar vasodilation with nitroglycerin/verapamil and verapamil alone [15] . Dalal et al found similar decreases in radial artery diameter with nicorandil compared to nitroglycerin/diltizem but there is less blood pressure drop with nicorandil [19] . Dharma et al found similar rates of procedural success with nitroglycerin with and without diltiazem [20] . Sekai et al found greater vasodilation with nitroglycerine compared to ISDN and verapamil [29] . In addition, the adverse events reported in each included study are presented in Table 5 .
We also analysed these studies for procedure failure rate i.e. switching from TRA to TRF, procedure duration, catheter information and radial artery occlusion, Table 4 . Only four studies compared procedure duration out of which two studies showed it was non-significant in both treatment and placebo arms, Byrne et al reported increased procedure duration in treatment arm.
No information was available regarding the procedure failure rates and radial artery occlusion in these studies.
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Discussion
In this largest and up-to-date review on intra-arterial vasodilators to reduce RAS, we have found that many agents have been evaluated as potential vasodilators to reduce RAS.
We found that the pooled rate of RAS in the placebo arm of several studies was 12% and only 5 mg of verapamil had lower pooled rates of RAS (4%). There were many single studies that evaluated the efficacy of different agents but many of these were underpowered.
Nitroglycerin appears to reduce RAS but other less studied agents such as ISMN and nicardipine require further investigations. Several different cocktails or combinations of drugs have been tried and the best combination is nitroglycerine and verapamil which lead to 9% RAS if administered at adequate doses. For other cocktails of medications, there is inconsistent evidence that one combination is superior to another.
Several previous reviews have evaluated RAS during transradial procedures. The review by Ho et al reported that the incidence of RAS was 4 to 20%, which is consistent with the findings of 12% in the pooled results of the placebo arm of the current study [33] . The Ho et al review also discusses RAS prevention strategies including the use of pharmacological agents including intra-arterial vasodilatory cocktails but caution the use of verapamil because it is contraindicated in severe left ventricular function and bradycardia [33] . Another review by Kristic et al pooled the results from 19 studies had reported that the incidence of RAS was 14.7% which is slightly higher than the current study [10] . The review by Kristic can reduce RAS by up to 3.8% [10] . This combination is also supported by another review [34] . Our study supports the use of this combination of drugs at the recommended doses, as rate of RAS was 9% using this regime in the current study.
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The advantages and disadvantages of vasodilatory agents in preventing RAS has been previous reviewed [35] . Nitroglycerine or glycerine tri-nitrate promote smooth muscle relaxation and hence vasodilation but there are risks of tachyphylaxis, withdrawal and hypotension. Verapamil is negatively inotropic and less effective than nifedipine but nifedipine is only available orally. Nicardipine is a strong calcium antagonist while diltiazem is negatively inotropic, less potent and has a slow onset. Nicorandil is less negatively inotropic compared to calcium channel antagonists. While there is no clear agreement on the optimal agent, verapamil-glyceryl trinitrate may represents the optimal combination [35] .
While our study has shown that many intra-arterial agents can be used to prevent radial artery spasm, the use of sublingual agents in intractable cases of radial spasm is unclear. There is a study by Al-Waili et al which found that sublingual verapamil and nifedipine may lower blood pressure in hypertensive patients and it may be possible that these agents could be used to reduce radial spasm [36] . It may be possible for use of sublingual nifedipine in cases of intractable radial artery spasm in hypertensive patients but more studies are needed.
Our study has several strengths and limitations. This is the largest review with 22
clinical trials with data from 8,777 participants. We were able to pool the results for risk of RAS across many studies and found that the most effective agents appear to be verapamil alone or nitroglycerine and verapamil combination.
Our study is limited by the quality of the evidence available in literature. There are several studies that are significantly underpowered. There were as low as 30 patients in one study [15] and has low as 10 patients in each arm in another study [12] . Furthermore, many of the included studies were not fully published and were only available in abstract form.
While, these studies may have limited information inclusion of these studies reduces publication bias. Furthermore, many of these studies were derived from well over a decade
ago and so the rates of 12% RAS reported in the placebo arms seem high in comparison to those encountered in daily practice by the authors of the manuscript. This may relate to the lack of radial specific equipment and sheaths used in these studies that would increase RAS rates, particularly when using sheaths without hydrophilic coatings [37] . An additional factor is that many centers use smaller diameter 5Fr radial sheaths and catheters for diagnostic cardiac catheterization that would decrease rates of RAS observed as would use of more contemporary thinner wall sheaths such as the Glidesheath Slender which combines an inner diameter compatible with 6Fr guiding catheter with an outer diameter close to current 5Fr sheaths where RAS rates have been reported as low as 4.4% [38] . Finally sheathless guide catheter usage may also result in lower rates of RAS than those reported in the 'placebo'
control arm with previous data reporting RAS rates of 5% [39] .
No data were available about radial spasm and radial artery occlusion in these studies in the setting of pharmacological prevention of RAS. Previous studies have suggested that RAS may increase the risk of radial artery occlusion, for example Rathore et al observed a high incidence of radial occlusion in patients with documented RAS in their randomized study investigating the influence of sheath coating and length on RAS rates (14.5% vs. 7.4%, p = 0.003) [37] .
Minimizing RAS either pharmacologically or via sheath/catheter selection certainly increases procedure success rate, reduces procedure duration and hence radiation exposure and minimizes the short and long term radial vascular complications. Our review highlights the gap in literature on these important outcomes in setting of reducing RAS pharmacologically and further studies are required to study this.
Conclusion
In this largest and up-to-date review on intra-arterial vasodilators use to reduce RAS, we have found that the verapamil at a dose of 5 mg or verapamil in combination with nitroglycerine are the best combinations to reduce RAS. The use of other agents to prevent RAS such as nicardipine, ISMN and magnesium requires more studies. Operators should consider optimal sheath and catheter selection, as well as pharmacological regime to minimize RAS particularly in procedures undertaken in patients at increased risk for RAS such as females, the elderly and those with small diameter radial artery sizes. M A N U S C R I P T RCT=randomized controlled trial, NR=not reported Nitroglycerin and nicardipine are effective at lowering RAS but combination is best.
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ISDN=isosorbide dinitrate, MAP=mean arterial pressure, ISMN=isosorbide mononitrate, RAS=radial artery spasm Only 1 patient (2%) from placebo group had hypotension after injection of the solution. A small hematoma was observed at the site of puncture in 2 cases (4%) but unclear in which group. Rosencher 2012 [26] There was also no significant difference in term of safety events and pain sensation between the different groups. Rosencher 2013 SPASM 3 [27] No significant difference was found between the three groups in terms of severe pain, crossover and safety events. Ruiz-Salmeron 2005 [28] There were only two serious events related to the procedure: one patient presented an extensive hematoma in the right forearm produced by radial
